Dr O’Connor, Senior Principal Scientist at AstraZeneca will present on the topic of breast cancer. He was also involved in DDReponse – New hope for hereditary breast and ovarian cancer patients.
Dr O’Connor has over 20 years experience in oncology research and development including an in-depth knowledge of DNA repair biology.
Prior to joining Astrazeneca he was Chief Scientist at KuDOS Pharmaceuticals, a drug discovery company based in Cambridge (UK). KuDOS developed inhibitors of the DNA damage response (DDR) including the oral PARP inhibitor olaparib that has shown significant activity in Phase II trials. In early 2006 KuDOS became a wholly-owned subsidiary of AstraZeneca when it was bought for $210m.
As Senior Principal Scientist (an AZ Director position) Dr O’Connor has been responsible for setting up and leading the DDR area within oncology. Dr O’Connor is also the Lead Scientist for olaparib which is entering Phase III clinical trials this year. On the Oncology bioscience he is part of the leadership team and supports the early phase projects within the oncology portfolio. Dr O’Connor has published more than 40 international papers in journals such as Nature Cell Biology, Cell and New England Journal of Medicine.
Latest updat dd 15.09.2015: Mark O’Connor is unable to contribute and will be ‘replaced’ by his colleague Darren Hogdson.